| 2019CG001 |
Chemotherapy |
Phase I/II
|
A Phase 1/2, Multi-Center, Dose-Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to < 18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD Mutations
(Protocol Number: AC220-A-U202/ADVL1822)
|
| 2019IS124 |
Chemotherapy |
Phase I/II
|
A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors; Protocol Number: LOXO-RET-18036 (J2G-OX-JZJJ)
|
| 2020IS022 |
Immunotherapy - Drugs;Other Ca |
Phase I/II
|
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
|
| 2020IS043 |
Blood and Marrow Transplant |
Phase I
|
MT2020-06: A PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF JSP191 FOR HEMATOPOIETIC CELL TRANSPLANTATION CONDITIONING TO ACHIEVE ENGRAFTMENT AND IMMUNE RECONSTITUTION IN SUBJECTS WITH SCID
|
| 2020IS054 |
Immunotherapy - Cellular/Vacci |
Phase I/II
|
MT2020-08 A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in subjects with Relapsed/Refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia
|
| 2020IS090 |
Immunotherapy - Cellular/Vacci |
Phase I
|
MT2020-24: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
|
| 2020IS101 |
Immunotherapy - Cellular/Vacci |
Phase I
|
MT2020-21: A PHASE 1,OPEN-LABEL,DOSE ESCALATING STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF THE COMBINATION OF CLBR001, AN ENGINEERED AUTOLOGOUS T-CELL PRODUCT, AND SWI019,AN ANTIBODY-BASED BIOLOGIC, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES
|
| 2020LS100 |
Supportive Care |
Phase I/II
|
MT2020-27: Phase I/II Trial Using E7777 to Enhance Regulatory T-Cell Depletion Prior to Tisagenlecleucel (Kymriah) Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
|
| 2020LS114 |
Immunotherapy - Cellular/Vacci |
Phase I
|
MT2020-33: Study of FT538 in Combination with Daratumumab in Acute Myeloid Leukemia
|
| 2021IS085 |
Chemotherapy;Supportive Care |
Phase I
|
A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and
Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in
Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in
Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and
Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C).
Protocol Number: I3Y-MC-JPCS
|
| 2021CG091 |
|
Phase I/II
|
A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
|
| 2021IS114 |
|
Phase I/II
|
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients with Locally Advanced or Metastatic Solid Tumours
|
| 2021LS032 |
Supportive Care |
Phase I
|
Study of Nutraceutical Intervention with High Phenolic Extra Virgin Olive Oil and Curcumin for Neurofibromatosis, type 1 (NF1)
|
| 2021LS006 |
Blood and Marrow Transplant |
Phase I/II
|
MT2021-01: PTCy + Sirolimus/VIC-1911 as GVHD prophylaxis in myeloablative PBSC transplantation
|
| 2021IS133 |
Immunotherapy - Cellular/Vacci |
Phase I/II
|
MT2021-25: Phase I/II Multicenter study evaluating the Safety and Efficacy of Alllogeneic GDA-201 Natural Killer cells in patients with relapsed/refractory B-Cell Non-Hodgkin Lymphoma
|
| 2021CG156 |
Chemotherapy;Supportive Care |
Phase I/II
|
PEPN2011 - A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
| 2021IS173 |
|
Phase I
|
A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants with Advanced Cancer
|
| 2021IS174 |
|
Phase I/II
|
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Protocol Number: CA224069
|
| 2021LS143 |
|
Phase I
|
A Phase I Study of HCW9218, a Bifunctional TGF-B; Antagonist/IL-15 Protein Complex, in Select Advanced Solid Tumors After Failing at Least Two Prior Therapies
|
| 2022CG008 |
Chemotherapy;Supportive Care |
Phase I/II
|
PEPN2111 - A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
|
| 2021LS103 |
|
Phase I
|
MT2021-27 Intraperitoneal FT538 with Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
|
| 2022CG084 |
Chemotherapy;Radiotherapy;Supp |
Phase I/II
|
ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
|
| 2022IS096 |
|
Phase I/II
|
MT2022-41 A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe Sickle Cell Disease
|
| 2022IS068 |
|
Phase I/II
|
MT2022-31 A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects with Transfusion Dependent b-Thalassemia
|
| 2022CG118 |
|
Phase I/II
|
PEPN2121 : A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
|
| 2022IS091 |
|
Phase I/II
|
MT2022-53: A Phase 1/2 Single Arm Open-Label Clinical Trial Of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
|
| 2022CG158 |
|
Phase I
|
PEPN22P1: Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods
|
| 2022IS114 |
Immunotherapy - Cellular/Vacci |
Phase I
|
MT2022-56: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
|
| FVMMCORC-2022-WF1901 |
|
Phase I
|
Internet-delivered Management of Pain Among Cancer Treatment Survivors
|
| 2022IS148 |
|
Phase I/II
|
MT2022-58: A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitor(s) in Patients with HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors
|
| 2022UC137 |
|
Phase I
|
PRE-I-SPY TRIAL - PRE-Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis: A Phase I/Ib platform trial
|
